

Freya Biosciences ApS

Fruebjergvej 3, 2100 Copenhagen

CVR no. 41 25 75 47

Annual report 2020

(As of the establishment of the Company 23 March - 31 December 2020)

Approved at the Company's annual general meeting on 8 July 2021

Chair of the meeting:

DocuSigned by:
Peter Bisgaard
6FDA19310B0848F...





Contents

Statement by the Board of Directors and the Executive Board	2
Independent auditor's report	3
Management's review	5
Financial statements for the period 23 March - 31 December 2020	6
Income statement	6
Balance sheet	7
Statement of changes in equity	9
Notes to the financial statements	10



Statement by the Board of Directors and the Executive Board

Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Freya Biosciences ApS for the financial year as of the establishment of the Company 23 March - 31 December 2020.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2020 and of the results of the Company's operations for the financial year as of the establishment of the Company 23 March - 31 December 2020.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the annual general meeting.

Copenhagen, 8 July 2021
Executive Board:

DocuSigned by:
Colleen Acosta
8EBBC5988C76493.....
Colleen Acosta
CEO

Board of Directors:

DocuSigned by:
Peter Bisgaard
8FDA19310B0648F.....
Peter Finsel Bisgaard
Chair

DocuSigned by:
Nick Haft
941BD5B3DE9246E.....
Nicholas Haft

DocuSigned by:
Mark Smith
B0EBE738B514442.....
Mark Smith

DocuSigned by:
Colleen Acosta
8EBBC5988C76493.....
Colleen Acosta

DocuSigned by:
H. Richter
F6952847F89248C.....
Henriette Elsebeth Richter



Independent auditor's report

To the shareholders of Freya Biosciences ApS

Opinion

We have audited the financial statements of Freya Biosciences ApS for the financial year as of the establishment of the Company 23 March - 31 December 2020, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2020 and of the results of the Company's operations for the financial year as of the establishment of the company 23 March - 31 December 2020 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- ▶ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.



Independent auditor's report

- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- ▶ Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.


Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 8 July 2021
EY Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28



Christian Schwenn Johansen
State Authorised Public Accountant
mne33234



Management's review

Company details

Name	Freya Biosciences ApS
Address, Postal code, City	Fruebjergvej 3, 2100 Copenhagen
CVR no.	41 25 75 47
Established	23 March 2020
Registered office	Copenhagen
Board of Directors	Peter Finsel Bisgaard, Chair Nicholas Haft Mark Smith Colleen Acosta Henriette Elsebeth Richter
Executive Board	Colleen Acosta, CEO
Auditors	EY Godkendt Revisionspartnerselskab Dirch Passers Allé 36, P.O. Box 250, 2000 Frederiksberg, Denmark

Management commentary

Financial review

The income statement for 2020 shows a loss of DKK 1,894,743, and the balance sheet at 31 December 2020 shows equity of DKK 16,760,512.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.



Financial statements for the period 23 March - 31 December 2020

Income statement

Note	DKK	2020 9 months
	Other external expenses	<u>-576,803</u>
	Gross profit	-576,803
2	Staff costs	-872,582
	Amortisation/depreciation and impairment of property, plant and equipment	-15,178
	Research costs	<u>-653,213</u>
	Profit/loss before net financials	-2,117,776
3	Financial expenses	<u>-34,902</u>
	Profit/loss before tax	-2,152,678
	Tax for the year	<u>257,935</u>
	Profit/loss for the year	<u><u>-1,894,743</u></u>
	Recommended appropriation of profit/loss	
	Retained earnings/accumulated loss	<u>-1,894,743</u>
		<u><u>-1,894,743</u></u>



Financial statements for the period 23 March - 31 December 2020

Balance sheet

Note	DKK	<u>2020</u>
	ASSETS	
	Fixed assets	
4	Property, plant and equipment	
	Fixtures and fittings, other plant and equipment	437,475
		<u>437,475</u>
	Investments	
	Deposits	105,283
		<u>105,283</u>
	Total fixed assets	<u>542,758</u>
	Non-fixed assets	
	Receivables	
	Tax credit receivable	257,935
	Other receivables	904,613
	Prepayments	2,575,649
		<u>3,738,197</u>
	Cash	<u>12,912,957</u>
	Total non-fixed assets	<u>16,651,154</u>
	TOTAL ASSETS	<u><u>17,193,912</u></u>



Financial statements for the period 23 March - 31 December 2020

Balance sheet

Note	DKK	<u>2020</u>
	EQUITY AND LIABILITIES	
	Equity	
	Share capital	252,172
	Share premium account	18,403,083
	Retained earnings	<u>-1,894,743</u>
	Total equity	<u>16,760,512</u>
	Liabilities other than provisions	
	Current liabilities other than provisions	
	Trade payables	285,282
	Other payables	<u>148,118</u>
		<u>433,400</u>
		433,400
	TOTAL EQUITY AND LIABILITIES	<u>17,193,912</u>

- 1 Accounting policies
- 5 Contractual obligations and contingencies, etc.
- 6 Contingent assets
- 7 Collateral



Financial statements for the period 23 March - 31 December 2020

Statement of changes in equity

DKK	Share capital	Share premium account	Retained earnings	Total
Cash payments concerning formation of enterprise	90,000	0	0	90,000
Capital increase	162,172	18,768,021	0	18,930,193
Expenses, capital increase	0	-364,938	0	-364,938
Transfer through appropriation of loss	0	0	-1,894,743	-1,894,743
Equity at 31 December 2020	252,172	18,403,083	-1,894,743	16,760,512



Financial statements for the period 23 March - 31 December 2020

Notes to the financial statements

1 Accounting policies

The annual report of Freya Biosciences ApS for 2020 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

As the company was founded in 2020, no comparative figures has been included in the annual report for the year.

Reporting currency

The financial statements are presented in Danish kroner (DKK).

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses.

Income statement

Research costs

The item includes research and development costs that do not qualify for capitalisation as well as amortisation of capitalised development costs.

Other external expenses

Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc.

Staff costs

Staff costs include wages and salaries, including compensated absence and pension to the Company's employees, as well as other social security contributions, etc. The item is net of refunds from public authorities.



Financial statements for the period 23 March - 31 December 2020

Notes to the financial statements

1 Accounting policies (continued)

Depreciation

The item comprises depreciation of property, plant and equipment.

The basis of depreciation, which is calculated as cost less any residual value, is depreciated on a straight line basis over the expected useful life. The expected useful lives of the assets are as follows:

Fixtures and fittings, other plant and equipment	3-5 years
--	-----------

Depreciation is based on the residual value of the asset and is reduced by impairment losses, if any. The depreciation period and the residual value are determined at the acquisition date and are reassessed annually. Where the residual value exceeds the carrying amount of the asset, no further depreciation charges are recognised.

In the case of changes in the depreciation period or the residual value, the effect on the depreciation charges is recognised prospectively as a change in accounting estimates.

Financial expenses

Financial expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc.

Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

Balance sheet

Property, plant and equipment

Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.

Impairment of fixed assets

The carrying amount of intangible assets, property, plant and equipment and investments in subsidiaries and associates is assessed for impairment on an annual basis.

Impairment tests are conducted on assets or groups of assets when there is evidence of impairment. The carrying amount of impaired assets is reduced to the higher of the net selling price and the value in use (recoverable amount).

The recoverable amount is the higher of the net selling price of an asset and its value in use. The value in use is calculated as the present value of the expected net cash flows from the use of the asset or the group of assets and the expected net cash flows from the disposal of the asset or the group of assets after the end of the useful life.

Previously recognised impairment losses are reversed when the reason for recognition no longer exists. Impairment losses on goodwill are not reversed.



Financial statements for the period 23 March - 31 December 2020

Notes to the financial statements

1 Accounting policies (continued)

Receivables

Receivables are measured at amortised cost.

The Company has chosen IAS 39 as interpretation for impairment of financial receivables.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtors' domicile and credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.

Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.

Prepayments

Prepayments recognised under "Assets" comprise prepaid expenses regarding subsequent financial reporting years.

Cash

Cash comprise cash and short term securities which are readily convertible into cash and subject only to minor risks of changes in value.

Equity

Proposed dividends

Dividend proposed for the year is recognised as a liability once adopted at the annual general meeting (declaration date). Dividends expected to be distributed for the financial year are presented as a separate item under "Equity".



Financial statements for the period 23 March - 31 December 2020

Notes to the financial statements

1 Accounting policies (continued)

Income taxes

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.

Tax credits for research and development costs is recognised as a tax receivable of 22 % of the costs eligible for tax credits, when such cost has been realised.

Liabilities

Financial liabilities are recognised at the date of borrowing at the net proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan. Financial liabilities also include the capitalised residual lease liability in respect of finance leases.

Other liabilities are measured at net realisable value.



Financial statements for the period 23 March - 31 December 2020

Notes to the financial statements

2	Staff costs	
	Wages/salaries	867,842
	Pensions	1,515
	Other staff costs	3,225
		<u>872,582</u>
		<u>2020</u>
	Number of employees at the balance sheet date	<u>4</u>
3	Financial expenses	
	Other financial expenses	34,902
		<u>34,902</u>
4	Property, plant and equipment	
	DKK	Fixtures and fittings, other plant and equipment
	Additions	<u>452,653</u>
	Cost at 31 December 2020	<u>452,653</u>
	Depreciation	<u>15,178</u>
	Impairment losses and depreciation at 31 December 2020	<u>15,178</u>
	Carrying amount at 31 December 2020	<u>437,475</u>
	Depreciated over	<u>3-5 years</u>
5	Contractual obligations and contingencies, etc.	
	Other financial obligations	
	Other rent liabilities:	
	Rent liabilities	<u>131,557</u>

Rent liabilities include a rent obligation with 3 months termination.

6 Contingent assets

The company has tax loss carry-forwards totalling DKK 956290. The nominal value thereof is 22%, totalling DKK 210.384. The amount has not been recognised in the balance sheet due to the uncertainty as to application of the tax losses.

7 Collateral

The Company has not provided any security or other collateral in assets at 31 December 2020.